Egg allergy is common, with an estimated prevalence of 1% to 9% around the world, and is the leading cause of IgE-mediated food allergy in Australian children. [1] [2] [3] Although spontaneous resolution and tolerance occurs in 60% to 75% of infants with egg allergy by the time they reach the teenage years, 4 the burden of the disease is significant in early childhood. 5 Early published cohorts examining early introduction of complementary foods within the first 4 months of life suggested that early feeding might increase the likelihood of allergic disease but did not specifically examine food allergy. 6 Observational cohort data have generally reported no protective effect of delayed introduction of foods, such as wheat, egg, and milk, and no difference rates of other foods in patients with atopic disease (asthma, eczema, and rhinitis) 7 or an association between early dietary introduction and reduced food allergy. For egg specifically, 2 cohorts have described an association between early introduction of egg and reduced egg allergy. 8, 9 Reduction of risk from peanut allergy through early introduction of dietary peanut is supported by epidemiologic association 10 and now by using robust randomized controlled trial (RCT) findings from the Learning Early About Peanut Allergy study. 11 Evidence from the recently published Enquiring About Tolerance (EAT) study, 12 with early introduction of multiple allergenic foods within a short time frame, including egg, is less compelling.
There are issues with reverse causation in observational cohorts, and several early egg introduction RCTs nearing or just completed will assist in determining whether early egg introduction plays a role in egg allergy primary prevention. These include Start time of egg protein to prevent egg allergy (STEP) (ACTRN12610000388011), Hen's Egg Allergy Prevention (HEAP) (DRKS00005668), and our own current study.
We hypothesized that the introduction of regular egg into the diets of infants who are at high risk of allergic disease would result in decreased sensitization to egg, promoting egg tolerance rather 
METHODS

Study design
The Beating Egg Allergy Trial (BEAT) is a randomized, double-blind, single-site, parallel-arm, controlled trial conducted in Sydney, Australia (ACTRN-12611000535976). The study was powered to determine whether introduction of dietary egg within the first 8 months of life influenced sensitization to egg at 12 months in infants with a first degree-relative with atopic disease. The study was approved by the Sydney Children's Hospital's Network Human Ethics Committee (HREC/10/CHW/4). Written informed consent was obtained from parents.
Enrollment and study procedures
Enrollment took place between December 2011 and May 2014. Mothers of newborn infants were approached in postnatal wards after delivery of healthy term infants. Infants with at least 1 first-degree relative with a history of any atopic disease (food allergy, asthma, atopic eczema, or allergic rhinitis [AR]) were invited to attend for screening at 4 months of age. Infants with a skin prick test (SPT) response to commercial egg white (EW; Stallergenes, Antony, France) of 2 mm or greater (mean wheal diameter) by using the lancet method were excluded.
After screening, infants were randomized (by computer with a permuted block method stratified by sex) to receive daily rice powder (placebo) or 350 mg of egg protein (given as pasteurized whole egg powder; Farm Pride, Keysborough, Australia) from the successful introduction of their first weaning food. With the exception of 2 dieticians specifically allocated to labeling the study treatments, all other study staff were blind to the treatment allocation. Rice or egg powder were dispensed in identical containers and not opened by assessment staff. Unblinding (eg, because of an adverse event) was undertaken for 1 episode of food protein-induced enterocolitis syndrome (FPIES; rice) during the study; otherwise, allocation remained concealed until the end of the study.
Parents were instructed to give their child a strict egg-free diet over the intervention period (4-8 months) and were provided with egg avoidance advice and written instructions. A daily diary was provided to record compliance and any adverse events. Infants were assessed at 8 months, and all study participants (except those who had reacted to study powder with IgE-mediated symptoms during the intervention period or with an EW-SPT response > _5 mm) were encouraged to have diets liberalized and to introduce egg per the Australian National Health and Medical Research Council Infant Feeding Guidelines. The study intervention was continued until any form of lightly cooked egg had been successfully incorporated into the diet. Blinding allocation remained concealed at 8 months in all subjects.
Clinical assessments, including growth parameters, presence of atopic eczema on examination (by modified Hanifin and Rajka criteria), 13 and eczema severity scores (objective SCORAD), 14 were performed at 4, 8, and 12 months of age. All infants with a history of reaction to the study intervention, egg at dietary introduction after 8 months, and/or an EW SPT response of 3 mm or greater at 12 months of age were invited to undergo an oral food challenge (OFC) to lightly cooked whole egg (scrambled egg) under medical supervision (cumulative dose, 6 g of egg protein, which is equivalent to 1 egg, with doses increasing semilogarithmically at 20-minute intervals). Staff conducting OFCs were blind to allocation and SPT responses. Blood samples were collected at 12 months of age.
Immune parameters
IgG 4 and IgE measurements were performed with ImmunoCAP 250 (Thermo Fisher Scientific, Waltham, Mass) with F245, F1, F233, and F232 (ImmunoCAP; Phadia, Uppsala, Sweden).
Study outcomes
The primary study outcome was the proportion of infants in each group sensitized to EW on SPTs at 12 months (defined as an EW SPT response > _3 mm) at 12 months of age.
Secondary outcomes were as follows: 
Statistical analysis
The statistical analysis plan (see this article's Online Repository at www.jacionline.org) was formulated before database lock and study unblinding. The primary outcome was analyzed according to randomized treatment by using x 2 tests on all participants with available data (full analysis set [FAS] ) and on all infants with outcome data whose parents reported taking the allocation on at least 80% of days (per-protocol [PP] group). The FAS is the analysis set that is as complete and close as possible to the ITT ideal of having primary outcome data on all randomized subjects. Absolute risk reduction was calculated as the risk of not being sensitized in the egg arm minus the risk of being nonsensitized in the placebo arm, and the number needed to treat was obtained by calculating reciprocals.
To attempt to account for missing outcome data at 12 months, the primary outcome was also analyzed by using logistic regression weighted by the inverse probability of having the observed outcome data. The probabilities were derived from a logistic regression model in which selected prespecified baseline characteristics were tested as predictors of having observed primary outcome data. An additional ''pessimistic'' sensitivity analysis was performed, in which missing outcome data were imputed by using a random sample from a binomial distribution with a probability parameter equal to the sensitization rate in the other treatment arm.
The safety population included all observed adverse events in all subjects according to randomized allocation.
Secondary outcomes were analyzed according to randomized treatment in all participants for whom the relevant outcome was available. There was no adjustment for multiple statistical comparisons. Comparisons between groups used Wilcoxon rank sum nonparametric tests for continuous outcomes and x 2 tests for categorical outcomes. Missing data/baseline characteristics of those infants with missing primary outcome data at 12 months were compared with those in the FAS. Subgroup analysis on the outcomes of EW-SPT responses of 3 mm or greater and probable egg allergy at 12 months were performed by using binary logistic regression to test for any interaction between eczema at 4 months and randomized treatment. Predefined exploratory analyses were performed by using binary logistic regression to test for the effects of selected baseline characteristics on the same outcomes and were adjusted for randomized treatment. The planned sample size of 160 patients per group had 80% power at a 2-sided 5% a value to detect a difference in sensitization by using EW-SPTs at 12 months from 15% in the control group to 5% in the egg group, with an allowance of 15% for loss to follow-up. All analyses were performed in SAS software (version 9.3; SAS Institute, Cary, NC).
Study design rationale
Introduction of egg between 4 and 8 months was chosen as the intervention of interest because of developmental readiness and harmonization (in terms of time points) with other studies investigating early introduction and after advice from the ethics committee that prolonging avoidance of egg past 8 months of age would not be acceptable. We did not perform OFCs at study entry at 4 months for a number of reasons: (1) a single large exposure to egg might influence study outcome and particularly sensitization and (2) it was considered that an oral challenge at 4 months, an additional blood collection, or both would be a significant deterrent against participation and in any event was unlikely to receive ethics approval.
RESULTS
Study population
The study population is outlined in the CONSORT diagram (Fig 1) . Approximately 4000 families were approached, of whom 1434 indicated some interest and 332 attended the initial screening visit. Of the 332 infants screened, 13 were excluded based on an EW-SPT response of 2 mm or greater, with a median EW-SPT response of 6 mm (interquartile range [IQR], 3.5-9 mm), and 319 infants (166 male infants) underwent randomization at a median age of 3.8 months (IQR, 3.6-4.0 months; range, 2.7-6.0 months). Twenty-six percent of infants had eczema evident on examination at randomization. Overall, 44% of infants Screening visits occurred at 4 months of age. All infants had at least 1 first-degree relative with a history of asthma, eczema, AR, or food allergy. Infants with an EW-SPT response of 2 mm or greater were excluded. All other infants were randomized 1:1 to receive daily placebo or pasteurized whole egg powder (egg protein, 350 mg) from the first successful introduction of solids until 8 months of age. Diets were liberalized at 8 months of age. Infants were assessed at 12 months with examination, SPTs (EW, peanut, cow's milk, soy, and wheat), and open OFCs.
had at least 1 parent born outside Australasia, with parents born in greater Asia (South East Asia, India, and China) representing the largest group of those with non-Australasian region of birth. Twenty-four percent of infants had both parents born outside Australasia. The median age at delivery was 39 weeks (39.0 weeks for egg and 39.1 weeks for placebo), and median birth weight was 3.4 kg (egg, 3.3 kg; placebo, 3.4 kg). Forty-five percent of the cohort was receiving only breast milk at randomization. The baseline demographics of each group are shown in Table I .
Two hundred twenty-eight (71%) infants had a mother with a history of atopy: 45% with AR, 32% with asthma, 24% with eczema, and 18% with food allergy. One hundred ninety-seven (62%) infants had a father with a history of atopy: 39% with AR, 24% with asthma, 19% with eczema, and 11% with food allergy. In 41% of infants, both parents had a history of asthma, eczema, food allergy, and/or AR. Thirty-nine percent of infants had 1 or more siblings with a history of atopic disease.
The median age of introduction of intervention was 4.0 months (IQR, 4.0-4.5 months) and 4.0 months (IQR, 4.0-4.8 months) for the egg and placebo groups, respectively, with 75% of infants successfully taking the intervention by 5 months of age. Compliance (>80% of days of intervention from introduction until 8 months) was similar across the 2 groups: 81% for egg powder and 89% for placebo in those attending for assessment at 8 months.
Twenty-seven infants were randomized but did not receive the intervention at any stage because their parents decided not to participate further (egg, 13; placebo, 14). There were 30 infants randomized to placebo and 35 infants randomized to egg for whom no data were available at 12 months of age. Baseline characteristics of complete cases (FAS) compared with those lost to follow-up/withdrawn/without primary outcome data were not different, except with respect to mother and father's region of birth, where birth outside Australasia for the father (P < .001) or mother (P < .02) was associated with greater loss to follow-up at 12 months. All 15 infants who were lost to follow-up between the 8-and 12-month visits had EW-SPT responses of 0 mm at the 8-month visit.
Thirteen infants were excluded during screening and before randomization. Of these 13 excluded infants, 70% had eczema evident on examination.
Study outcomes
Primary outcome. Two hundred forty-four of 319 infants had primary outcome data available for analysis. There was a reduction in the proportion of infants sensitized to EW at 12 months in those receiving egg (10.7% [13/122] Fig 2) . The relative risk reduction was 48% (95% CI, 3% to 72%), and the absolute risk reduction (risk of being nonsensitized in the egg arm minus risk of being nonsensitized in the placebo arm) was 9.8% (95% CI, 8.2% to 18.9%), with a number needed to treat of 11 (95% CI, 6-122). There was also a significant difference between groups determined by using PP analysis in the 208 infants who had consumed study powder on at least 80% of days and had outcome data available (OR, 0.24; 95% CI, 0.09-0.61; P 5 .0015).
The primary outcome analysis was also significant with inverse probability weighted analysis (OR, 0.48; 95% CI, 0.26-0.89; P 5 .02). The only factor that remained after backward selection was father's region of birth (Australia/New Zealand born vs elsewhere), where 172 (84%) of 207 infants with fathers born in Australia/New Zealand had primary outcome data compared with 74 (64%) of 109 infants with fathers born elsewhere (father's region of birth was missing for 3 babies). The sensitivity analysis was performed on the 243 cases with outcome data and known father's region of birth and weighted by the reciprocal of the probability of having outcome data. This provides additional weight in the analysis to babies with fathers born overseas because they are underrepresented in the data set. The results of this analysis (OR, 0.48; 95% CI, 0.26-0.89; P 5 .02) were comparable with those of the unweighted analysis (OR, 0.46; 95% CI, 0.22-0.95; P 5 .03).
Secondary outcomes. The outcome for probable egg allergy determination was available on 253 infants at 12 months (egg, 129; placebo 124; Fig 1) . Twenty-one (8.5%) infants were assessed as having probable egg allergy at 12 months. There was no evidence of a difference in probable egg allergy between the placebo and egg groups at 12 months when analyzed by using FAS (13/124 [10.5%] compared with 8/130 [6.2%] infants, respectively; P 5 .20). By means of PP analysis, there was a reduction in probable egg allergy at 12 months in those infants receiving egg (11 compared with 2, P 5 .013); however, this is attributable, at least in part, to the exclusion from the PP analysis of those infants randomized to receive egg who reacted to the intervention within the first weeks and therefore did not receive ongoing treatment. Of the 8 infants randomized to receive egg with probable egg allergy at 12 months, 6 reacted to the intervention (and were unable to continue with their allocated treatment) and 2 were compliant. Of the 21 infants classified as having probable egg allergy at 12 months of age, 7 had confirmed allergy on the OFC, and 13 had a convincing history of allergic reaction to egg, with an EW-SPT response of greater than 3 mm. One infant had no exposure; the family refused OFC because of an EW-SPT response of 6.5 mm at 12 months (see Table E1 in this article's Online Repository at www.jacionline.org for detailed characteristics of probable egg allergy). At 12 months, 205 of 253 infants had successfully incorporated lightly cooked egg into their diet, whereas 16 were only having products containing baked egg, and 32 were avoiding all egg. We invited parents of all 48 children not regularly ingesting lightly cooked egg at 12 months (irrespective of EW-SPT responses) or with a history of reacting to the study intervention from 4 to 8 months or egg on introduction at 8 months to have their infants undertake an egg OFC, but only 21 agreed to this. Of these 48 infants (excluding those who were not classified as having probable egg allergy and/or who did not undergo OFCs) only 3 had EW-SPT responses of greater than 1 mm, and none reported a subsequent reaction at home.
We explored whether age at introduction of the intervention had any effect on compliance. There was no difference between age at first introduction of the intervention between those infants deemed compliant in the PP group (median age, 119 days; IQR, 112-124 days) and those deemed noncompliant (median age, 119 days; IQR, 114-124 days) who had outcome data at 12 months.
At 12 months, of the 14 infants randomized to receive egg and who initially reacted to egg powder (and thus were unable to continue with the invention), 4 (29%) were egg tolerant, 7 (50%) had probable egg allergy, 2 (14%) were avoiding egg, and 1 (7%) was lost to follow-up.
Thirty-two percent and 37% of infants had eczema on examination at 8 and 12 months, respectively. There was no difference in the prevalence or severity of eczema between groups at 8 (P 5 .57 and P 5 .98) or 12 months (P 5 .52 and P 5 .77), respectively. Most eczema was mild, with a median SCORAD score of 7.4 (range, 1-31) at 12 months in both groups (Table II) .
The rate of overall sensitization to peanut (SPT response > _3 mm) in the combined cohort at 12 months was high at 8.6%, but there was no difference in peanut sensitization between the 2 intervention groups (P 5 .49). A peanut SPT response of 5 mm or greater at 12 months was present in 4.5% of infants. There were no differences between the intervention groups with regard to sensitization to cow's milk, wheat, or soy at 12 months, but absolute numbers were very small (n 5 6, 3, and 1, respectively).
There was no significant difference in EW-SPT responses between infants receiving egg or placebo at 8 months of age, directly after the intervention period (P 5 .69).
Infants in the egg intervention group (n 5 91) had higher IgG 4 levels and higher IgG 4 /IgE ratios to egg, ovalbumin, and ovomucoid when compared with those infants receiving placebo (n 5 93; P < .0001 for all analyses, Fig 3) . There was no significant difference in egg-specific IgE levels at 12 months (see Fig E1 in this article's Online Repository at www. jacionline.org).
In our prespecified subgroup analysis, we explored whether having eczema at 4 months of age was associated with any treatment modification effect. Eczema at 4 months was highly associated with both an EW-SPT response of 3 mm or greater and probable egg allergy at 12 months (P < .001); however, there was no treatment modification effect. Specifically, there was no interaction between treatment and eczema at 4 months on either an EW-SPT response of 3 mm or greater or probable egg allergy at 12 months (P 5 .6 and P 5 .17, respectively).
We explored whether there were any predictors of 12-month outcomes based on known baseline characteristics adjusted for randomized treatment. Eczema at 4 months was the only strong predictor of an EW-SPT response of 3 mm or greater (Table III) or probable egg allergy (see Table E2 in this article's Online Repository at www.jacionline.org).
Safety
No serious adverse events occurred during the study. All IgE-mediated reactions occurred within 1 hour of ingestion and consisted of urticaria, angioedema and erythema, rhinorrhea, and 1 instance of vomiting, with no cardiorespiratory involvement and no adrenaline required.
Fifteen (4.7%) infants reacted to allocated treatment within 1 week of commencing the intervention. Fourteen (4.4%) reactions were mild-to-moderate IgE-mediated reactions in infants randomized to receive egg (urticaria, angioedema, and vomiting). Families of these infants were advised to stop the intervention and continue an egg-free diet. They underwent further clinical assessment and repeat EW SPTs after reactions. One infant randomized to placebo (rice powder) had an FPIES-type reaction (delayed, recurrent, and profuse vomiting) and was advised stop the allocated treatment.
DISCUSSION
We have demonstrated that introduction of daily egg into the diets of infants at risk of egg allergy from 4 to 6 months of age was associated with a reduction in egg sensitization on skin testing and induction of a significant IgG 4 response to egg and the major egg protein components ovalbumin and ovomucoid at 12 months of age. This suggests a tolerogenic effect for those infants who were able to tolerate egg introduction without having an allergic reaction. Despite excluding infants who already had evidence of sensitization to egg (on SPTs) at study entry (4-6 months), nearly 10% of infants randomized to receive egg powder were already allergic to egg, although some transiently, and therefore were not amenable to this form of early intervention. For the remainder, there was a beneficial effect in induction of immunologic markers of tolerance, although our study size precluded us demonstrating a definitive effect on clinical egg allergy. Although infants randomized to egg were less likely to have probable egg allergy at 12 months by using PP analysis, we contend that this is a distortion caused by removal of infants who had early allergic reactions to intervention in the PP analysis and therefore cannot be used to conclusively show that egg allergy was reduced through early dietary introduction of egg. Importantly, the treatment effect was not influenced by the presence of eczema at 4 months, which was the strongest predictor in our study for egg sensitization and probable egg allergy at 12 months. This suggests that, where tolerated, early egg introduction is likely to be as beneficial in those infants with existing eczema.
Our findings of a significant increase in IgG 4 levels and IgG 4 / IgE ratios are consistent with those of the smaller Western Australian Solids Timing for Allergy Research (STAR) study, in which infants with moderate-to-severe eczema underwent early egg introduction, irrespective of baseline SPT responses. 16 We enhance this knowledge by demonstrating a similar phenomenon in infants with predominantly mild or no eczema and by extending the observations to the major egg protein components ovalbumin and ovomucoid. Additionally, our findings are consistent with those reported for the introduction of other allergenic foods, such as peanut. 11 Importantly, there was no significant harm associated with the introduction of egg in our study. Early introduction of egg was not associated with higher rates of eczema at 8 or 12 months of age or higher rates of sensitization to other foods at 12 months. No infant had a serious allergic reaction, either at home or during OFCs to egg, despite the use of pasteurized whole egg powder as the intervention. This is in contrast to the STAR study, in which several episodes of anaphylaxis were reported. This might relate to the highly atopic study population in the STAR study, in which all participants had moderate-to-severe eczema. In contrast, although the prevalence of eczema at 4 months in our study was high at 26%, it was mostly mild. Moreover, we used lightly cooked egg as our challenge substance at 12 months of age, which is in contrast to the STAR study, which used raw egg.
There are several useful additional observations that come from our cohort. We confirm a high rate of probable egg allergy and egg sensitization in Australian infants, which was first documented by the Melbourne-based HealthNuts cohort 1 but not elsewhere. The HealthNuts cohort was a population-based cohort, although we included only infants at high risk (ie, all participants having > _1 first-degree relative with a history of atopy). Therefore one would expect higher rates of sensitization and egg allergy in the placebo arm in our cohort, which is indeed the case. In that context the intervention could be viewed as reducing the overall rate of egg sensitization and allergy burden of a high-risk cohort down to approximately that of the Australian ''general'' infant population. 1 Peanut sensitization, which has significant relevance given current discussions about the nature and extent of possible screening for peanut sensitization in infants at risk of peanut allergy, was 8.7% at 12 months of age, with 4% of infants at greater than the reported 95% positive predictive value for peanut allergy among those less than 2 years of age (> _5 mm). 17, 18 Infant weaning is an emotionally charged area, with many rigid views of ''when, what, and how'' being delivered to parents by family elders, clinic nurses, mother support groups, and the like. As such, intervention studies, which seek to interfere with what parents had otherwise planned for early infant weaning, especially directly after the first successful solid food introduction, are difficult. Recruiting to such studies is difficult, and the large number of families we needed to approach during the recruitment phase illustrates this. The intervention requires significant encouragement and support for participating families; the commitment required from parents make it unlikely to be easily replicated for each different food allergen across different regions of the world. Within this context, despite our best efforts, we had 20% loss to follow-up over the study period. There are several points worth noting.
The largest loss, at nearly 10%, occurred between randomization and commencement of study intervention, where no powder at all was given to the randomized infant. This loss was similar between the 2 study groups, and it might be considered that these infants were lost at random, unrelated to their allocated treatment, and therefore unlikely to have affected study outcomes.
The baseline characteristics of those with missing data and those who completed the 12-month follow-up were similar except for region of the birth mother and particularly the father. This is potentially useful in planning future intervention studies, in which additional support and more frequent follow-up might be helpful.
Losses during the intervention period and after 8 months were equal between the study groups; specific reasons for this are speculative. Infants who had negative EW-SPT responses at 8 months and who were successfully eating egg at home thereafter might have been less likely to attend the follow-up visit at 12 months, leading to an overestimate in the rates of sensitization and eczema in both groups at 12 months. Indeed, all infants lost to follow-up between 8 and 12 months had negative EW-SPT responses.
There are several potential weaknesses of this study. Like other primary prevention studies, the parents most attracted to participate might not be representative of the general population, with a higher proportion of well-educated, middle to high socioeconomic bracket parents in this study. However, these traits are also associated with higher rates of allergic disease, which confounds any attempt to assess the degree to which this skewing might affect the generalizability of the study findings. We were pleased to recruit a relatively high proportion of nonwhite infants, which differentiates this cohort in some respects from other studies.
Although the prespecified sample size was not met for the 12-month primary outcome, this did not affect our primary outcome because of the high rate of sensitization to egg in this high-risk cohort. We used a relatively small amount of dietary egg and asked parents to provide it daily rather than only once or twice a week, as would be the likely natural exposure to dietary egg at 4 to 8 months. The dose was chosen to approximate half of a small egg per week, which would be in line with recommended daily intakes. Although 350 mg of egg protein is relatively small, it is more than 5 times higher than the published dose at which 50% of patients with egg allergy are estimated to react (median effective dose), 19 which suggests that the active intervention was not acting as a de facto oral immunotherapy at this dose. Moreover, the reactions we observed within the first week of introduction suggest that this is unlikely. Reassuringly, we did not see any serious allergic reactions because of the introduction of pasteurized whole egg, unlike reports from the West Australian STAR study and other (as yet) unpublished studies, such as HEAP, in which a much higher dose of egg was used. Although egg consumption once or twice weekly might reflect real life, we believed that compliance with the intervention would be improved with daily dosing. The majority of parents were able to maintain compliance at greater than 80% of daily doses and were able to introduce the intervention within the first month of solids introduction. Seventy-five percent of infants in this study had the intervention successfully introduced before 5 months of age, which is in contrast to 55% in the EAT study. However, EAT required 5 foods to be incorporated (and not 1) and used larger amounts of food rather than blinded powder, and therefore the 2 studies are not directly comparable.
We were unable to challenge all infants with possible egg allergy at 12 months because many parents declined a further challenge, having recently observed an obvious IgE-mediated allergic reaction to egg in their child. It is possible that some infants labeled as having ''probable egg allergy'' might have been able to tolerate egg at the 12-month OFC; however, clinical egg allergy was not the predetermined primary outcome for this study. Not all participants agreed to have blood collected at the 12-month visit, and therefore the IgG 4 and IgE data might not be entirely representative of the whole cohort; however, the differences identified between the 2 groups were very marked.
There is no perfect study design to assess early dietary introduction of allergenic food, which can circumvent the fact that some infants will already be allergic to the food in question. One possible solution could be for all study infants to undergo randomization only after tolerance has been demonstrated (say) to daily egg for 1 week. However, this degree of exposure to egg could be sufficient for those who are subsequently randomized to placebo to alter tolerance (and thus such infants could not then be considered as early egg avoidant) or, of more concern, might increase sensitization and the risk of subsequent clinical allergy. This issue should be kept in mind when designing future primary prevention intervention studies.
We believe our study differs sufficiently from the STEP and HEAP studies and provides additional useful information about the relative merits of early introduction of egg into the infants diet and subsequent egg allergy. We targeted those infants not yet significantly sensitized to egg at 4 months but most at risk of subsequent egg allergy by deliberately including infants with eczema and a family history of allergic disease. 20 Unlike the STEP trial, we excluded subjects who were sensitized to egg at 4 months but, importantly, included infants with eczema. Given that eczema is strongly associated with the development of egg allergy and potentially more severe reactions to egg, 16 we believe this is a very important population in which to offer an intervention, if tolerated. The HEAP trial did not assess egg SPT responses before intervention and used a far greater amount of egg protein (2.5 g thrice weekly) as the study intervention. In addition, a significant proportion of infants in our study had 1 or both parents born in Asia, a likely risk factor for food allergy in Australian infants. 21, 22 Overall, our data suggest that, for infants at risk of egg allergy and who are able to tolerate it, introduction of regular egg immediately after successful first weaning solids at a low dose might be beneficial and with no evidence of harm.
We thank Alvin Benig for his assistance in sample collection and management. We thank all the families and infants who participated in the study.
Clinical implications: Epidemiologic evidence suggests that delayed introduction of dietary egg can promote rather than protect from egg allergy in infants at risk of allergic disease, as has been recently shown for peanut. We conducted an RCT, which demonstrated dietary introduction of egg between 4 and 6 months of age was associated with reduced sensitization to egg (SPT responses) and resulted in marked induction of eggspecific IgG 4 levels at 12 months in infants at high risk of allergy.
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Statistical considerations
All analyses will be performed in SAS software, version 9.3. There will be no adjustment for multiple statistical comparisons. There will be no direct imputation of missing data, but the primary analysis will be performed on the complete cases alone and on the complete cases with an inverse probability weighting (see details below). Additional derived parameters will be the ratio of IgG 4 divided by IgE for egg (EW IgG 4 /whole egg IgE), ovalbumin, and ovomucoid.
Descriptive statistics will be medians, IQRs, and minimum and maximum values for each parameter in each treatment and plotted with histograms and scatterplots.
Comparisons between groups will use Wilcoxon rank sum (Mann-Whitney) nonparametric tests.
Subgroup analyses
Twelve-month SPT responses of 3 mm or greater and probable egg allergy outcomes will be analyzed in the FAS (observed) population with ''eczema present at 4 months'' as a subgroup using binary logistic regression to test for randomized treatment, baseline eczema, and their interaction. If an interaction is found, then treatment effects will be calculated separately according to baseline eczema status by using x 2 tests.
Exploratory analyses
Predictors of allergy outcomes: binary logistic regression analyses will be used in the FAS (observed) population to explore the effect of maternal education, presence of smokers in the household, presence of pets in the household, and ethnicity on the outcomes of SPT reactions and allergy. These analyses will be adjusted for randomized treatment. 
